Pre-market hot trades in US stocks: Enveric Biosciences up 9.99% in pre-market; TRAILBLAZER MERGER CORP I USD0.0001 CL A (S/R21/04/2028) up 9.38% in pre-market

Tracking Unusual Activity
2025.10.16 12:07
portai
I'm PortAI, I can summarize articles.

Enveric Biosciences pre-market up 9.99%; TRAILBLAZER MERGER CORP I USD0.0001 CL A (S/R21/04/2028) pre-market up 9.38%; Linkage Global pre-market up 148.48%; rYojbaba pre-market up 132.26%; Praxis Precision Medicines pre-market up 125.89%

Pre-market Hot Trades in US Stocks

Enveric Biosciences is up 9.99% in pre-market trading. According to recent important news:

  1. On October 15, Enveric Biosciences announced it would take legal action against AbbVie, claiming that AbbVie's depression candidate drug bretisilocin infringes on its patents. This news drove Enveric's stock price up about 20%. Source: Business Wire

  2. On October 16, Enveric Biosciences hired the intellectual property law firm Fish and Richardson to respond to Gilgamesh Pharmaceuticals' post-grant review application regarding its patents. This move further solidifies the company's position in the patent dispute. Source: Business Wire

  3. No other significant news recently. The biotechnology industry has been quite volatile lately, and risks should be noted.

TRAILBLAZER MERGER CORP I USD0.0001 CL A (S/R21/04/2028) is up 9.38% in pre-market trading, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation.

Top Gainers in Pre-market US Stocks

Linkage Global is up 148.48% in pre-market trading, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation.

rYojbaba is up 132.26% in pre-market trading, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation.

Praxis Precision Medicines is up 125.89% in pre-market trading. According to recent important news:

  1. On October 16, Praxis Precision Medicines announced that its experimental drug ulixacaltamide achieved positive results in two key Phase 3 trials, significantly improving patients' daily functioning. This news caused the company's stock price to double in pre-market trading. Source: Reuters

  2. On October 16, the company plans to submit a new drug application to the FDA and has requested a pre-NDA meeting. This move further enhances market confidence in the future commercialization of the drug. Source: Company announcement

  3. On October 16, ulixacaltamide demonstrated good tolerability in trials, with no serious adverse events reported. This safety data provides investors with more confidence. Source: Company announcement. The biopharmaceutical industry has been active recently, with increased market volatility

Source: Tracking Unusual Activity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.